Mebicar

Systematic (IUPAC) name
1,3,4,6-Tetramethyltetrahydroimidazo[4,5-d]imidazole-2,5(1H,3H)-dione
Clinical data
Legal status	US: Unscheduled
Identifiers
CAS Number	10095-06-4
PubChem	CID: 122282
ChemSpider	109042
Chemical data
Formula	C8H14N4O2
Molecular mass	198.222 g/mol
SMILES CN1C2C(N(C1=O)C)N(C(=O)N2C)C
InChI InChI=1S/C8H14N4O2/c1-9-5-6(11(3)7(9)13)12(4)8(14)10(5)2/h5-6H,1-4H3 Key:XIUUSFJTJXFNGH-UHFFFAOYSA-N

Mebicar (mebicarum) is an anxiolytic medication produced by Latvian pharmaceutical company Olainfarm and sold in Latvia and Russia under the brand name Adaptol. Mebicar is not approved for use in the United States.

Mebicar has an effect on the structure of limbic-reticular activity, particularly on hypothalamus emotional zone, as well as on all 4 basic neuromediator systems – γ aminobutyric acid (GABA), choline, serotonin and adrenergic activity. Mebicar decreases the brain noradrenaline level, exerts no effect on the dopaminergic systems, increases the brain serotonin level, and does not elicit cholinolytic action.

Mebicar purportedly has anti-anxiety (anxiolytic) properties. It is also used to aid smoking cessation. In addition Mebicar may be useful in the treatment of ADHD symptoms. In contrast with typical anxiolytic medication like benzodiazepines Mebicar is non-habit forming, non-sedating and does not impair motor function.

See also

• Fabomotizole
• Phenibut
• Selank
• Tenoten
• Validol